Hope for a Normal Future | City Journal
When the FDA issued its guidance for final approval of any Covid-19 vaccine, many estimated that the broad impact of effective Covid vaccines on daily life would not be experienced by most until early 2022. The cascade of factors that led to this view were the FDA guidance that any approved vaccine might only be 50 percent effective, that production and delivery of the vaccine was extremely challenging, and that a significant number of individuals were hesitant to get the vaccine. With the recent reports by two vaccine makers (Pfizer and Moderna) of the results of their preliminary analysis of their Phase 3 trials showing greater than 90 percent protection and now today s announcement of a third, AstraZeneca s, also boasting 90 percent effectiveness there is cause for more optimism about the timeline for resuming life.
I don’t think I’ve ever looked forward so much to getting a shot.